Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 995-1006 |
| Seitenumfang | 12 |
| Fachzeitschrift | Biometrical journal |
| Jahrgang | 42 |
| Ausgabenummer | 8 |
| Publikationsstatus | Veröffentlicht - 18 Dez. 2000 |
Abstract
An important issue in dose finding is whether a further dose increment leads to a relevant increase in efficacy. Clinical efficacy should not be considered by point zero null hypotheses. Instead, shifted hypotheses for the difference or the ratio can be used. Because the a priori definition of a relevance threshold is frequently difficult, confidence intervals should be used for a posteriori interpretation. Sample size estimation - a-priori or by adaptive interim analysis- is inherent, because the effective dose steps are arbitrary in un-designed studies. For simultaneous confidence intervals without order restriction the exact distributions under the null and the alternative hypothesis is proposed for the general unbalanced one-way design.
ASJC Scopus Sachgebiete
- Mathematik (insg.)
- Statistik und Wahrscheinlichkeit
- Entscheidungswissenschaften (insg.)
- Statistik, Wahrscheinlichkeit und Ungewissheit
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Biometrical journal, Jahrgang 42, Nr. 8, 18.12.2000, S. 995-1006.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - One-sided simultaneous confidence intervals for effective dose steps in unbalanced designs
AU - Hothorn, Ludwig A.
AU - Bretz, Frank
PY - 2000/12/18
Y1 - 2000/12/18
N2 - An important issue in dose finding is whether a further dose increment leads to a relevant increase in efficacy. Clinical efficacy should not be considered by point zero null hypotheses. Instead, shifted hypotheses for the difference or the ratio can be used. Because the a priori definition of a relevance threshold is frequently difficult, confidence intervals should be used for a posteriori interpretation. Sample size estimation - a-priori or by adaptive interim analysis- is inherent, because the effective dose steps are arbitrary in un-designed studies. For simultaneous confidence intervals without order restriction the exact distributions under the null and the alternative hypothesis is proposed for the general unbalanced one-way design.
AB - An important issue in dose finding is whether a further dose increment leads to a relevant increase in efficacy. Clinical efficacy should not be considered by point zero null hypotheses. Instead, shifted hypotheses for the difference or the ratio can be used. Because the a priori definition of a relevance threshold is frequently difficult, confidence intervals should be used for a posteriori interpretation. Sample size estimation - a-priori or by adaptive interim analysis- is inherent, because the effective dose steps are arbitrary in un-designed studies. For simultaneous confidence intervals without order restriction the exact distributions under the null and the alternative hypothesis is proposed for the general unbalanced one-way design.
KW - Dose finding
KW - Effective dose steps
KW - Multivariate t-distribution
UR - http://www.scopus.com/inward/record.url?scp=0034556815&partnerID=8YFLogxK
U2 - 10.1002/1521-4036(200012)42:8<995::AID-BIMJ995>3.0.CO;2-4
DO - 10.1002/1521-4036(200012)42:8<995::AID-BIMJ995>3.0.CO;2-4
M3 - Article
AN - SCOPUS:0034556815
VL - 42
SP - 995
EP - 1006
JO - Biometrical journal
JF - Biometrical journal
SN - 0323-3847
IS - 8
ER -